Sign in Subscribe
Drugs

Advances in Renal Cell Carcinoma Management

Strategic Insights

— 1 min read

Renal cell carcinoma (RCC) is the eighth most commonly diagnosed malignancy in the United States, with localized disease found in about 55% of patients. Standard therapy has undergone significant change, with cytokines like interferon alfa and aldesleukin largely displaced by molecularly targeted agents such as sorafenib tosylate, sunitinib malate, and temsirolimus. Researchers from Northeastern University have emphasized the importance of these new treatments in improving progression-free survival rates. According to their study, estimated five-year survival rates for patients with RCC are 89.6% for localized disease, 60.8% for regional disease, and 9.5% for patients with distant metastases.

Key Takeaways:

  • RCC is the eighth most commonly diagnosed malignancy in the United States, with localized disease found in about 55% of patients.
  • Surgical resection is the mainstay of therapy for stage I-III RCC.
  • Standard therapy has shifted from cytokines to molecularly targeted agents such as sorafenib tosylate, sunitinib malate, and temsirolimus, which offer lower rates of toxicity and improved progression-free survival.
  • Estimated five-year survival rates for patients with RCC are 89.6% for localized disease, 60.8% for regional disease, and 9.5% for patients with distant metastases.
  • Bevacizumab has shown activity in patients with advanced disease.
  • Researchers are currently assessing the activity of combinations of available agents and new targeted agents as adjuvant therapy and for the management of advanced RCC.
  • High-dose aldesleukin is used to treat select patients, with its major value being the durability of responses in the few patients who achieve a complete remission.

Statistics:

  • 55% of RCC patients have localized disease.
  • 19% of RCC patients have locally advanced disease.
  • 20% of RCC patients have metastatic disease.
  • Estimated five-year survival rates for patients with RCC are:

+ 89.6% for localized disease.

+ 60.8% for regional disease.

+ 9.5% for patients with distant metastases.

Sources:

  • R.J. Cersosimo et al., "Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2", American Journal of Health - System Pharmacy, vol. 66, no. 18, pp. 1625-1633, 2009.
  • American Society Health-System Pharmacists, 7272 Wisconsin Avenue, Bethesda, MD 20814, USA.

Read more